In October, due to demand from existing healthcare partners, CTS began testing blood donors for antibody to Babesia microti under an Investigational New Drug exemption as a release test.
Continue to meet or exceed healthcare partners’ expectations by providing on-time test results appr...
In 2016, CTS tested more source plasma samples (4.9 million) than blood donor samples (4.5 million).
CTS Tampa lab implements Dengue testing on behalf of a healthcare partner in an endemic area.
In August CTS begins source plasma testing as a new line of business to one of the largest plasma fr...
In April, CTS becomes the first blood donor testing organization in the US to implement Zika testing...
In January, CTS is incorporated as a non-profit organization owned by Vitalant and OneBlood (formerl...